Drug for Ulcerative Colitis Is Focus of OASIS Clinical Trial

Drug for Ulcerative Colitis Is Focus of OASIS Clinical Trial
A new study being conducted in more than 100 clinical centers across the world is evaluating the safety and efficacy of a new investigational drug for the treatment of mild to severely active ulcerative colitis. The OASIS clinical trial aims to recruit 240 adults, ages 18 to 80 years old, who have been diagnosed with ulcerative colitis for at least six months and have failed to respond to at least one medication. Ulcerative colitis, a type of inflammatory bowel disease (IBD), is a chronic disease that affects the colon and is characterized by tissue inflammation and ulceration, leading to frequent day-to-day difficulties, such as diarrhea, abdominal cramps, and frequent bowel movements. It is the result of an exacerbated response of the immune system and, therefore, the usual therapy focuses on controlling inflammation via intravenous delivery of anti-inflammatory and immune-suppressive drugs, although current therapies have a few limitations regarding efficacy, side effects, and route of administration. The development of an oral medication such as the one being studied in the OASIS trial would greatly improve treatment convenience in patients with ulcerative colitis. The investigational drug, not yet approved by the U.S. Food and Drug Administration (FDA), is APD334, an orally available S1P1 receptor modulator, developed by Arena Pharmaceuticals. It acts by modulating the S1P1 receptor, which has been shown to be involved in a series of biological responses including lymphocyte trafficking from lymph nodes to circulating blood. By toning down this recruitment, the drug causes the immune response to be less aggressive, and consequentl
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *